Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Evalstotug by BioAtla for Uveal Melanoma: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II...
Evalstotug by BioAtla for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
Evalstotug by BioAtla for Renal Cell Carcinoma: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
Evalstotug by BioAtla for Gastric Cancer: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Evalstotug by BioAtla for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According...
Evalstotug by BioAtla for Cervical Cancer: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Evalstotug by BioAtla for Solid Tumor: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Evalstotug by BioAtla for Melanoma: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...
Risk adjusted net present value: What is the current valuation of BioAtla's Evalstotug?
Evalstotug is a monoclonal antibody commercialized by BioAtla, with a leading Phase II program in Non-Small Cell Lung Cancer. According...